HAHayato Abe

Hayato Abe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hayato Abe has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preoperative FIB ‐4 Index as a Potential Factor Associated With Severe Postoperative Complications and Endogenous Organ Failure After Hepatectomy for Hepatocellular Carcinoma

    by Masanori Nakamura, Yukiyasu Okamura, Osamu Aramaki, Nao Yoshida, Yusuke Mitsuka, Hayato Abe, Shunsuke Yamagishi, Yasuhiro Okumura, Kyongsun Pak, Shinobu Masuda

    Background: Liver fibrosis influences tolerance to surgical stress, dictating postoperative complication risks after hepatectomy for hepatocellular carcinoma (HCC). While conventional systems assess hepatic function, they may not fully capture structural fibrosis. This study evaluated the whether preoperative Fibrosis‐4 (FIB‐4) index is associated with severe complications and “endogenous organ failure” (EOF: systemic decompensation unaccompanied by localized surgical‐site complications). Methods: This retrospective study analyzed 1778 HCC patients undergoing hepatectomy between 2001 and 2020. A restricted cubic spline (RCS) model identified the optimal preoperative FIB‐4 cutoff for predicting major complications (Clavien‐Dindo [C‐D] Grade ≥ IIIa). Following stratification by this cutoff, intergroup comparisons and multivariable logistic regression analyses were performed to identify independent predictors of major and severe (C‐D Grade ≥ IIIb) complications. Results: RCS analysis suggested a FIB‐4 threshold of 5.0 for an increased trend in complication risk. The High FIB‐4 index group (≥ 5.0, n = 385) showed a higher frequency of severe complications (7.0% vs. 3.4%) and EOF (3.1% vs. 0.4%) compared to the Low FIB‐4 index group (< 5.0, n = 1393). Among patients developing life‐threatening complications (C‐D Grade ≥ IV), 92.3% of the High FIB‐4 index group presented with EOF. In multivariable analyses, FIB‐4 ≥ 5.0 was consistently and independently associated with both major and severe complications. Conclusion: A preoperative FIB‐4 ≥ 5.0 was associated with an increased incidence of severe complications, particularly EOF, after hepatectomy. This simple index could serve as a clinical indicator of systemic vulnerability, enhancing surgical risk stratification beyond traditional functional markers.


  • Open Access

    Clinical implications of oncological resectability criteria in hepatocellular carcinoma treated with transarterial chemoembolization

    by Hayato Abe, Yukiyasu Okamura, Osamu Aramaki, Nao Yoshida, Yusuke Mitsuka, Shu Inagaki, Masataka Shindate, Shunsuke Yamagishi, Yasuhiro Okumura, Kosuke Narumiya, et al.

    Background The oncological resectability criteria for hepatocellular carcinoma (BR-HCC) have mainly been evaluated in surgical populations, and their clinical relevance in patients undergoing transarterial chemoembolization (TACE) remains unclear. This study evaluated the prognostic significance and clinical implications of the BR-HCC criteria in TACE-treated patients. Methods We retrospectively analyzed the data of 1,018 patients with HCC who underwent initial treatment between 2014 and 2023, including 222 patients treated with TACE and 638 patients who underwent liver resection (LR) as a reference cohort. Patients were classified into resectable (R), borderline resectable 1 (BR1), and borderline resectable 2 (BR2) groups according to pre-treatment imaging findings. Overall survival (OS) and time to treatment failure (TTF) were analyzed using Kaplan–Meier and Cox regression analyses. Results The BR-HCC criteria successfully stratified prognosis in the TACE cohort. The median OS was 50.0, 28.2, and 10.0 months in the R, BR1, and BR2 groups, respectively (P < 0.05), with similar trends observed for TTF. Impaired liver function, elevated AFP levels, and macrovascular invasion were independently associated with poor OS. Hepatic adverse events after TACE occurred significantly more frequently in the BR1/BR2 groups than in the R group. Exploratory propensity score–matched analyses demonstrated longer OS after LR than after TACE within the BR cohort. Conclusions The BR-HCC criteria provide clinically meaningful prognostic stratification in patients undergoing TACE and may help identify patients less suitable for repeated TACE-based strategies, thereby supporting individualized multidisciplinary treatment approaches, including systemic therapy.

  • Worse Prognosis of Patients With Hepatocellular Carcinoma and Portal Vein Invasion Underestimated by Imaging

    by Masanori Nakamura, Yukiyasu Okamura, Osamu Aramaki, Nao Yoshida, Yusuke Mitsuka, Hayato Abe, Shu Inagaki, Shunsuke Yamagishi, Yasuhiro Okumura, Masahiro Okada, et al.

    Background: Portal vein invasion is closely linked to poor prognosis in hepatocellular carcinoma (HCC). However, no study has directly compared preoperative imaging with postoperative histopathological diagnoses of portal vein invasion. This study evaluated the prognostic impact of underdiagnosed portal vein invasion in patients undergoing hepatectomy. Methods: We retrospectively reviewed 1328 patients who underwent initial hepatectomy for HCC from January 2000 to December 2020. Portal vein invasion was classified as Image‐Vp0–4 based on preoperative imaging and vp0–4 based on postoperative pathology. Underdiagnosis was defined as IVp < vp; otherwise, IVp ≥ vp. Gross invasion was defined as vp2–4, and non‐gross invasion as vp0/1. Results: Pathological staging stratified overall survival (OS) more clearly than imaging (median OS: vp0 = 7.9 years; vp1 = 5.6; vp2 = 2.5; vp3 = 1.6; vp4 = 0.5), while Image‐Vp showed less consistent trends (Vp0–4 = 7.9; 7.6; 9.5; 1.6; 0.5 years). Underdiagnosis occurred most frequently in Image‐Vp0 and vp1 cases (16.7%). Patients with IVp < vp had significantly worse OS than those with IVp ≥ vp (5.6 vs. 7.9 years, p < 0.001). Among vp0/1 patients, OS was significantly shorter in underdiagnosed cases (5.8 vs. 7.9 years, p < 0.001), whereas in vp2–4 cases, underdiagnosis had no significant effect (3.9 vs. 1.6 years, p = 0.317). Conclusions: Underdiagnosis of vp1 was associated with significantly reduced survival in HCC patients, despite negative imaging findings. These results highlight the critical role of postoperative histopathology in accurately assessing portal vein invasion.

  • Open Access

    Comparison between Intravoxel Incoherent Motion and Splenic Volumetry to Predict Hepatic Fibrosis Staging in Preoperative Patients

    by Takayuki Arakane, Masahiro Okada, Yujiro Nakazawa, Kenichiro Tago, Hiroki Yoshikawa, Mariko Mizuno, Hayato Abe, Tokio Higaki, Yukiyasu Okamura, Tadatoshi Takayama

    Intravoxel incoherent motion (IVIM) and splenic volumetry (SV) for hepatic fibrosis (HF) prediction have been reported to be effective. Our purpose is to compare the HF prediction of IVIM and SV in 67 patients with pathologically staged HF. SV was divided by body surface area (BSA). IVIM indices, such as slow diffusion-coefficient related to molecular diffusion (D), fast diffusion-coefficient related to perfusion in microvessels (D*), apparent diffusion-coefficient (ADC), and perfusion related diffusion-fraction (f), were calculated by two observers (R1/R2). D (p = 0.718 for R1, p = 0.087 for R2) and D* (p = 0.513, p = 0.708, respectively) showed a poor correlation with HF. ADC (p = 0.034, p = 0.528, respectively) and f (p < 0.001, p = 0.007, respectively) decreased as HF progressed, whereas SV/BSA increased (p = 0.015 for R1). The AUCs of SV/BSA (0.649–0.698 for R1) were higher than those of f (0.575–0.683 for R1 + R2) for severe HF (≥F3–4 and ≥F4), although AUCs of f (0.705–0.790 for R1 + R2) were higher than those of SV/BSA (0.628 for R1) for mild or no HF (≤F0–1). No significant differences to identify HF were observed between IVIM and SV/BSA. SV/BSA allows a higher estimation for evaluating severe HF than IVIM. IVIM is more suitable than SV/BSA for the assessment of mild or no HF.


  • Tumor stiffness measurement using magnetic resonance elastography can predict recurrence and survival after curative resection of hepatocellular carcinoma

    by Hayato Abe, Kazu Shibutani, Shintaro Yamazaki, Tatsuo Kanda, Mitsuhiko Moriyama, Masahiro Okada, Masahiko Sugitani, Shingo Tsuji, Tadatoshi Takayama, Yukiyasu Okamura


  • Open Access

    Acute Liver Failure and Acute-on-Chronic Liver Failure in COVID-19 Era

    by Tatsuo Kanda, Reina Sasaki-Tanaka, Tomotaka Ishii, Hayato Abe, Masahiro Ogawa, Hirayuki Enomoto

    Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF), respectively, occur in patients with normal liver and patients with chronic liver diseases, including cirrhosis


  • Open Access

    A proposed model on MR elastography for predicting postoperative major complications in patients with hepatocellular carcinoma

    by Kazu Shibutani, Masahiro Okada, Jitsuro Tsukada, Tomoko Hyodo, Kenji Ibukuro, Hayato Abe, Naoki Matsumoto, Yutaka Midorikawa, Mitsuhiko Moriyama, Tadatoshi Takayama

    Objective: To develop a model for predicting post-operative major complications in patients with hepatocellular carcinoma (HCC). Methods: In all, 186 consecutive patients with pre-operative MR elastography were included. Complications were categorised using Clavien‒Dindo classification, with major complications defined as ≥Grade 3. Liver-stiffness measurement (LSM) values were measured on elastogram. The indocyanine green clearance rate of liver remnant (ICG-Krem) was based on the results of CT volumetry, intraoperative data, and ICG-K value. For an easy application to the prediction model, the continuous variables were converted to categories. Moreover, logistic regression analysis and fivefold cross-validation were performed. The prediction model’s discriminative performance was evaluated using the area under the receiver operating characteristic curve (AUC), and the calibration of the model was assessed by the Hosmer‒Lemeshow test. Results: 43 of 186 patients (23.1%) had major complications. The multivariate analysis demonstrated that LSM, albumin–bilirubin (ALBI) score, intraoperative blood loss, and ICG-Krem were significantly associated with major complications. The median AUC of the five validation subsets was 0.878. The Hosmer-Lemeshow test confirmed no evidence of inadequate fit (p = 0.13, 0.19, 0.59, 0.59, and 0.73) on the fivefold cross-validation. The prediction model for major complications was as follows: −2.876 + 2.912 [LSM (>5.3 kPa)]+1.538 [ALBI score (>−2.28)]+0.531 [Intraoperative blood loss (>860 ml)]+0.257 [ICG-Krem (<0.10)]. Conclusion: The proposed prediction model can be used to predict post-operative major complications in patients with HCC. Advances in knowledge: The proposed prediction model can be used in routine clinical practice to identify post-operative major complications in patients with HCC and to strategise appropriate treatments of HCC.


  • Predictive value of combined computed tomography volumetry and magnetic resonance elastography for major complications after liver resection

    by Kazu Shibutani, Masahiro Okada, Jitsuro Tsukada, Kenji Ibukuro, Hayato Abe, Naoki Matsumoto, Yutaka Midorikawa, Mitsuhiko Moriyama, Tadatoshi Takayama

    Purpose To retrospectively compare the predictive value of computed tomography volumetry (CTV), magnetic resonance elastography (MRE) of the liver, and their combination for major complications after liver resection. Methods We enrolled 108 consecutive patients who underwent anatomical liver resection for liver tumors and preoperative contrast-enhanced CT and MRE. The future liver remnant (FLR) ratio was calculated by CTV, while the liver stiffness measurement (LSM) was obtained by MRE. FLR ratio alone, LSM alone, and combined FLR ratio and LSM were evaluated to predict major complications (Clavien–Dindo grade ≥ IIIa). Univariate and multivariate analyses of hepatic biochemical parameters and imaging data were performed to identify predictors of major complications. Receiver operating characteristic analyses of FLR ratio, LSM, and their combination were performed, and the sensitivity and specificity were calculated. Results Twenty-two (20.4%) of the 108 patients experienced major complications. According to multiple regression analysis, the FLR ratio (odds ratio [OR] 0.96, 95% confidence interval [CI] 0.91–0.99, p = 0.040) and LSM (OR 1.72, 95% CI 1.01–2.94, p = 0.047) were independent predictors of major complications. The combined FLR ratio and LSM were predictive of major complications, with an area under the curve (AUC) of 0.818, sensitivity of 68.2%, and specificity of 84.9%. The AUC and specificity for combined FLR ratio and LSM were larger than those for FLR ratio (AUC: 0.711, specificity: 80.2%) and LSM (AUC: 0.793, specificity: 80.2%). Conclusion Combined CTV and MRE analysis can improve the AUC and specificity for predicting major complications after anatomical liver resection.


  • Open Access

    Effects of Pyrrole-Imidazole Polyamides Targeting Human TGF-β1 on the Malignant Phenotypes of Liver Cancer Cells

    by Keiko Takagi, Yutaka Midorikawa, Tadatoshi Takayama, Hayato Abe, Kyoko Fujiwara, Masayoshi Soma, Hiroki Nagase, Toshio Miki, Noboru Fukuda

    Synthetic pyrrole-imidazole (PI) polyamides bind to the minor groove of double-helical DNA with high affinity and specificity, and inhibit the transcription of corresponding genes. In liver cancer, transforming growth factor (TGF)-β expression is correlated with tumor grade, and high-grade liver cancer tissues express epithelial-mesenchymal transition markers. TGF-β1 was reported to be involved in cancer development by transforming precancer cells to cancer stem cells (CSCs). This study aimed to evaluate the effects of TGF-β1-targeting PI polyamide on the growth of liver cancer cells and CSCs and their TGF-β1 expression. We analyzed TGF-β1 expression level after the administration of GB1101, a PI polyamide that targets human TGF-β1 promoter, and examined its effects on cell proliferation, invasiveness, and TGF-β1 mRNA expression level. GB1101 treatment dose-dependently decreased TGF-β1 mRNA levels in HepG2 and HLF cells, and inhibited HepG2 colony formation associated with downregulation of TGF-β1 mRNA. Although GB1101 did not substantially inhibit the proliferation of HepG2 cells compared to untreated control cells, GB1101 significantly suppressed the invasion of HLF cells, which displayed high expression of CD44, a marker for CSCs. Furthermore, GB1101 significantly inhibited HLF cell sphere formation by inhibiting TGF-β1 expression, in addition to suppressing the proliferation of HLE and HLF cells. Taken together, GB1101 reduced TGF-β1 expression in liver cancer cells and suppressed cell invasion; therefore, GB1101 is a novel candidate drug for the treatment of liver cancer.


  • Clinical application of magnetic resonance elastography in chronic liver disease

    by Hayato Abe, Yutaka Midorikawa, Masahiro Okada, Tadatoshi Takayama

    Recent evidence highlighted that the accurate assessment of liver fibrosis is important for evaluating the progression of chronic liver disease. During the past decade, many non‐invasive methods have been developed to reduce the need for core‐needle biopsy in fibrosis staging and to overcome its limitations, such as invasiveness, high cost, low reproducibility, and poor patient consent. The diagnostic performance of magnetic resonance elastography (MRE) is promising for use in clinical practice to evaluate not only liver fibrosis, but also survival and major clinical end‐points such as liver decompensation, portal hypertension, development of hepatocellular carcinoma, and surgical outcomes. Together with other clinical markers, MRE can be used to better categorize patients with advanced fibrosis and cirrhosis, and assign them to different classes of risk for significant clinical outcomes. This review discusses clinical applications of MRE in the management strategy of patients with chronic liver disease.